MetaCap

enGene Therapeutics (ENGN) vs Invivyd (IVVD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

enGene Therapeutics (ENGN) has outperformed Invivyd (IVVD) over the past year, losing 75.0% versus a loss of 83.5%. Invivyd is the larger company by market cap ($122.0 million vs $116.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENGN-75.00%IVVD-83.49%
+83%-4%-91%
Nov 21, 20251 yearNov 20, 2026
ENGN-82.35%IVVD-94.99%
+203%+46%-110%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENGN versus IVVD key metrics
MetricENGNIVVD
Share price$1.74$0.4127
Market cap$116.61M$122.01M
1-day change-1.14%-7.45%
YTD return-80.73%-83.29%
1-year return-75.00%-83.49%
5-year return—-98.36%
EPS (TTM)$-2.07$-0.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$53.43M
Revenue growth (YoY)—+110.47%
Net income (latest FY)$-117.30M$-52.49M
Operating margin—-103.99%
Net margin—-98.25%
52-week high$12.25$3.01
52-week low$1.40$0.4127
Distance from 52-week high-85.80%-86.29%
Analyst consensusbuystrong_buy
Avg. price target upside+146.55%+2323.07%
Average volume1.12M5.20M
Shares outstanding67.02M295.63M
Employees81122
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Invivyd

IVVD stock →

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees

ENGN vs IVVD FAQ

Which is bigger, enGene Therapeutics or Invivyd?

Invivyd (IVVD) is larger, with a market capitalization of $122.01M compared with $116.61M for enGene Therapeutics (ENGN).

Which stock has performed better over the past year, ENGN or IVVD?

ENGN returned -75.00% over the past 12 months, compared with -83.49% for IVVD (price return, excluding dividends). Past performance does not predict future results.

Are enGene Therapeutics and Invivyd in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons